MA39040A1 - Nouveau traitement combiné pour la leucémie aiguë myéloïde (lam) - Google Patents

Nouveau traitement combiné pour la leucémie aiguë myéloïde (lam)

Info

Publication number
MA39040A1
MA39040A1 MA39040A MA39040A MA39040A1 MA 39040 A1 MA39040 A1 MA 39040A1 MA 39040 A MA39040 A MA 39040A MA 39040 A MA39040 A MA 39040A MA 39040 A1 MA39040 A1 MA 39040A1
Authority
MA
Morocco
Prior art keywords
aml
combination therapy
myeloid leukemia
acute myeloid
new combination
Prior art date
Application number
MA39040A
Other languages
English (en)
Inventor
Kathryn E Packman
Brian Higgins
Gwen Nichols
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52014047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39040(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA39040A1 publication Critical patent/MA39040A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La présente invention concerne un produit pharmaceutique qui comprend : a) en tant que premier composant, un inhibiteur de l'interaction mdm2-p53 ; et b) en tant que second composant, de la cytarabine ; sous forme de préparation combinée pour l'utilisation simultanée ou séquentielle dans le traitement du cancer, en particulier de la lam.
MA39040A 2013-12-05 2016-05-17 Nouveau traitement combiné pour la leucémie aiguë myéloïde (lam) MA39040A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361912152P 2013-12-05 2013-12-05
PCT/EP2014/076063 WO2015082384A1 (fr) 2013-12-05 2014-12-01 Nouveau traitement combiné pour la leucémie aiguë myéloïde (lam)

Publications (1)

Publication Number Publication Date
MA39040A1 true MA39040A1 (fr) 2018-01-31

Family

ID=52014047

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39040A MA39040A1 (fr) 2013-12-05 2016-05-17 Nouveau traitement combiné pour la leucémie aiguë myéloïde (lam)

Country Status (31)

Country Link
US (5) US20160303158A1 (fr)
EP (1) EP3077004B1 (fr)
JP (3) JP6297695B2 (fr)
KR (1) KR101862955B1 (fr)
CN (1) CN105792847B (fr)
AR (1) AR098576A1 (fr)
AU (1) AU2014359422B2 (fr)
BR (1) BR112016009669B1 (fr)
CA (1) CA2926307C (fr)
CL (1) CL2016001345A1 (fr)
CR (1) CR20160173A (fr)
DK (1) DK3077004T3 (fr)
EA (1) EA201690785A1 (fr)
ES (1) ES2785203T3 (fr)
HK (1) HK1222808A1 (fr)
HR (1) HRP20200566T1 (fr)
HU (1) HUE049434T2 (fr)
IL (1) IL244888B (fr)
LT (1) LT3077004T (fr)
MA (1) MA39040A1 (fr)
MX (1) MX370618B (fr)
PE (1) PE20160591A1 (fr)
PH (1) PH12016500933A1 (fr)
PL (1) PL3077004T3 (fr)
PT (1) PT3077004T (fr)
RS (1) RS60142B1 (fr)
SG (1) SG11201604504VA (fr)
SI (1) SI3077004T1 (fr)
TW (2) TWI678204B (fr)
WO (1) WO2015082384A1 (fr)
ZA (1) ZA201602829B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101525754B1 (ko) 2007-03-28 2015-06-09 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
CN108570097A (zh) 2010-08-13 2018-09-25 爱勒让治疗公司 拟肽大环化合物
MX358886B (es) 2011-10-18 2018-08-31 Aileron Therapeutics Inc Macrociclos peptidomimeticos.
EP2914256B1 (fr) 2012-11-01 2019-07-31 Aileron Therapeutics, Inc. Acides aminés disubstitués et procédés de préparation et d'utilisation de ceux-ci
EP3077004B1 (fr) * 2013-12-05 2020-02-19 F.Hoffmann-La Roche Ag Nouvelle thérapie combinatoire pour le treatment de la leucémie myéloïde aiguë (aml)
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
CN112972378A (zh) 2014-09-24 2021-06-18 艾瑞朗医疗公司 拟肽大环化合物及其制剂
JP2017533889A (ja) 2014-09-24 2017-11-16 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその使用
EP3294318A4 (fr) 2015-03-20 2019-04-03 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques et leurs utilisations
JP6971970B2 (ja) * 2015-09-03 2021-11-24 エルロン・セラピューティクス・インコーポレイテッドAileron Therapeutics, Inc. ペプチド模倣大環状分子およびその使用
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
BR112018075206A2 (pt) * 2016-06-06 2019-03-19 Celgene Corporation tratamento de malignidade hematológica com 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
JP6848047B2 (ja) * 2016-08-08 2021-03-24 フェイ シアオ， スピロインドロンポリエチレングリコールカーボネート系化合物及びその組成物、調製方法及びその使用
HUE055509T2 (hu) 2016-11-15 2021-12-28 Novartis Ag HDM2-p53-interakció-inhibitorok dózisa és adagolási rendje
JP6617208B2 (ja) * 2017-03-31 2019-12-11 ノバルティス アーゲー 血液腫瘍におけるｈｄｍ２−ｐ５３相互作用阻害剤の用量およびレジメン
US11091522B2 (en) 2018-07-23 2021-08-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
EP3858361A4 (fr) 2018-09-28 2021-12-01 FUJIFILM Corporation Agent antitumoral contenant de la cytarabine, activateur d'effet antitumoral utilisé en combinaison avec la cytarabine, kit antitumoral, et agent antitumoral utilisé en combinaison avec le cytarabine
TW202118488A (zh) * 2019-07-26 2021-05-16 大陸商蘇州亞盛藥業有限公司 Mdm2抑制劑的藥物組合物及其在預防和/或治療疾病中的用途
JP2024519335A (ja) * 2021-05-13 2024-05-10 ンカルタ・インコーポレイテッド がん免疫療法のための投薬レジメン

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125888B2 (en) * 2002-05-02 2006-10-24 Merck & Co., Inc. Tyrosine kinase inhibitors
DE102005012681A1 (de) * 2005-03-18 2006-09-21 Weber, Lutz, Dr. Neue 1,5-Dihydro-pyrrol-2-one
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
CN101773408B (zh) * 2010-01-15 2012-04-04 平荧 多功能排针结合电凝固技术提升下垂皮肤的装置
JP2013523820A (ja) * 2010-04-09 2013-06-17 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン 疾患を処置する際に使用するためのｍｄｍ２阻害剤のバイオマーカー
JO2998B1 (ar) * 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
US20120010235A1 (en) * 2010-07-12 2012-01-12 Xin-Jie Chu N-substituted pyrrolidines
US8993614B2 (en) * 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
US9216170B2 (en) * 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
EP3077004B1 (fr) * 2013-12-05 2020-02-19 F.Hoffmann-La Roche Ag Nouvelle thérapie combinatoire pour le treatment de la leucémie myéloïde aiguë (aml)
US9657351B2 (en) * 2013-12-06 2017-05-23 Hoffman-La Roche Inc. MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist

Also Published As

Publication number Publication date
US20220031726A1 (en) 2022-02-03
SG11201604504VA (en) 2016-07-28
RS60142B1 (sr) 2020-05-29
JP2018111700A (ja) 2018-07-19
AU2014359422B2 (en) 2020-03-05
CR20160173A (es) 2016-06-08
CA2926307A1 (fr) 2015-06-11
JP6297695B2 (ja) 2018-03-20
DK3077004T3 (da) 2020-04-27
ES2785203T3 (es) 2020-10-06
US20160303158A1 (en) 2016-10-20
TWI627954B (zh) 2018-07-01
CA2926307C (fr) 2021-11-16
KR20160070190A (ko) 2016-06-17
BR112016009669A8 (pt) 2020-04-07
SI3077004T1 (sl) 2020-07-31
AU2014359422A1 (en) 2016-04-28
EP3077004B1 (fr) 2020-02-19
JP6918724B2 (ja) 2021-08-11
BR112016009669B1 (pt) 2023-01-24
AR098576A1 (es) 2016-06-01
US20200253999A1 (en) 2020-08-13
CN105792847A (zh) 2016-07-20
IL244888A0 (en) 2016-05-31
CN105792847B (zh) 2019-11-08
CL2016001345A1 (es) 2017-04-07
TW201526890A (zh) 2015-07-16
MX2016007170A (es) 2016-09-08
PT3077004T (pt) 2020-04-16
EA201690785A1 (ru) 2016-10-31
JP2016539160A (ja) 2016-12-15
PH12016500933A1 (en) 2016-06-27
ZA201602829B (en) 2017-04-26
MX370618B (es) 2019-12-17
HK1222808A1 (zh) 2017-07-14
EP3077004A1 (fr) 2016-10-12
KR101862955B1 (ko) 2018-05-31
HRP20200566T1 (hr) 2020-06-26
PE20160591A1 (es) 2016-06-11
LT3077004T (lt) 2020-05-11
TW201840310A (zh) 2018-11-16
US20230381215A1 (en) 2023-11-30
IL244888B (en) 2020-11-30
US20150157603A1 (en) 2015-06-11
TWI678204B (zh) 2019-12-01
HUE049434T2 (hu) 2020-09-28
WO2015082384A1 (fr) 2015-06-11
US9956243B2 (en) 2018-05-01
PL3077004T3 (pl) 2020-08-10
JP2021091690A (ja) 2021-06-17

Similar Documents

Publication Publication Date Title
MA39040A1 (fr) Nouveau traitement combiné pour la leucémie aiguë myéloïde (lam)
MA39783A (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
EP4219563A3 (fr) Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1
MA39211B1 (fr) Composés tricycliques comme agents anti-cancers
MA40768A (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA47356B1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
MA42811B1 (fr) Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
WO2015195848A8 (fr) Inhibiteurs de ezh2 utilisables à des fins de traitement du lymphome
MX2018009752A (es) 1,2,3,-triazoles sustituidos como moduladores de nmda selectivos de nr2b.
WO2015070224A3 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
MA40769A (fr) Indoles mono ou di-substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
BR112013008140A2 (pt) "compostos imidazotriazinona".
MA35638B1 (fr) 2-thiopyrimidinones
CR20190433A (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
CL2011002206A1 (es) Compuestos derivados de benzofurano sustituidos, moduladores del señalador igf1 o activador de la proteina quinasa b; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades del snc, tales como alzheimer, entre otras.
MA47736B1 (fr) Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1
MA37742A1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
MX2021015500A (es) Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b.
MA50406B1 (fr) Inhibiteurs pyrazole de magl
MA46548B1 (fr) Fsh pour le traitement de l'infertilité
AU2018256668A1 (en) Combination therapy comprising an inhibitor of JAK, CDK and PIM
MA38678A1 (fr) Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués
MA44079B1 (fr) Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine